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The growth inhibitory nature of injured adult mammalian central nervous system
(CNS) tissue constitutes a major barrier to robust axonal outgrowth and functional
recovery following trauma or disease. Prototypic CNS regeneration inhibitors are broadly
expressed in the healthy and injured brain and spinal cord and include myelin-associated
glycoprotein (MAG), the reticulon family member NogoA, oligodendrocyte myelin
glycoprotein (OMgp), and chondroitin sulfate proteoglycans (CSPGs). These structurally
diverse molecules strongly inhibit neurite outgrowth in vitro, and have been most
extensively studied in the context of nervous system injury in vivo. The physiological role of
CNS regeneration inhibitors in the naïve, or uninjured, CNS remains less well understood,
but has received growing attention in recent years and is the focus of this review.
CNS regeneration inhibitors regulate myelin development and axon stability, consolidate
neuronal structure shaped by experience, and limit activity-dependent modification of
synaptic strength. Altered function of CNS regeneration inhibitors is associated with
neuropsychiatric disorders, suggesting crucial roles in brain development and health.
Keywords: NogoA, MAG, OMgp, CSPGs, regeneration, synaptic plasticity
Neural Network Plasticity—a Delicate Balancing Act
Orchestrated by Many Players
Proper function of the adult mammalian CNS requires precise assembly, refinement, and
maintenance of an elaborate network of neuronal connections. During development, axon
guidance molecules facilitate the formation of intricate neuronal networks. After this initial
assembly, many circuits are refined in an activity-dependent manner during a short time period
of heightened plasticity, called the critical period (CP). At the end of the CP, the fine tuning
of networks is complete and they acquire their mature shape. Synaptic contacts in the mature
brain are stable over long time periods (Holtmaat and Svoboda, 2009), however, limited structural
remodeling does occur and is thought to form the cellular basis of learning and the acquisition
of new memories. Some degree of circuit plasticity is vital for proper brain function, and when
improperly regulated can result in defects in learning andmemory or cause nervous system diseases
such as autism or schizophrenia (Mironova and Giger, 2013; Zagrebelsky and Korte, 2014).
To ensure rapid and accurate propagation of electrical impulses among different neural
ensembles, most long axons are enwrapped with myelin sheaths. In addition to increasing the
speed of impulse propagation, myelin provides metabolic support for axons (Franklin et al., 2012;
Saab et al., 2013) and has neuroprotective properties (Franklin et al., 2012). Recent evidence shows
that neuronal activity-regulated mechanisms exist that influence the extent of CNS myelination
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(Wake et al., 2011; Lundgaard et al., 2013; Gibson et al.,
2014; Hines et al., 2015; Mensch et al., 2015), suggesting that
adaptive myelination represents an as of yet underexplored
form of activity-dependent nervous system plasticity. Indeed,
perturbation of experience-dependent oligodendrocyte (OL)
maturation may lead to neurological disorder (Long and Corfas,
2014).
Here we focus on the physiological function of CNS
regeneration inhibitors in the naïve mammalian CNS.
Vital roles for these molecules in the uninjured CNS raise
important considerations for manipulating their function during
therapeutic approaches directed toward augmenting neural
plasticity and enabling nervous system repair.
Synopsis of CNS Regeneration Inhibitors
MAG
The neurite outgrowth inhibitory properties of MAG were
discovered independently by the laboratories of Marie Filbin
(Mukhopadhyay et al., 1994) and Peter Braun (McKerracher
et al., 1994) more than 20 years ago. MAG is a type-1
transmembrane protein and a prominent member of the family
of sialic acid-binding Ig superfamily (siglec) proteins. MAG is
expressed by myelinating glia, Schwann cells in the periphery
and oligodendrocytes (OL) in the CNS. MAG is abundant in the
CNS and is enriched in Schmidt-Lanterman incisures and the
periaxonal membrane of myelin sheath, allowing for complexes
with receptors to form on the axonal surface (Trapp et al., 1989).
The direct apposition of MAG and the axon membrane led
to the early hypothesis that MAG plays an important role in
regulating axon-myelin interactions and myelin development.
In vivo studies with Mag knockout mice revealed surprisingly
normal myelin development, yet closer examination uncovered
a delay in OL differentiation and transient hypomyelination
of the optic nerve in these mutants (Li et al., 1994; Montag
et al., 1994; Pernet et al., 2008). At the ultrastructural level,
peripheral and central nervous systemmyelin sheaths inMag null
mice display numerous subtle structural abnormalities, including
aberrant myelin outfolds and uncompactedmyelin wraps (Pernet
et al., 2008). Additionally, loss of MAG delays node of Ranvier
formation and alters distribution of nodal proteins, including
paranodin and sodium channels (Marcus et al., 2002). Aging
studies in Mag knockout mice revealed increased axonal “drop
out” and axonal atrophy, indicating that MAG plays a crucial
role in maintenance and long-term stability of the axon-glial unit
(Fruttiger et al., 1995).
Our understanding of the molecular mechanisms employed
byMAG to exert its different functions is still incomplete. Several
receptors for MAG have been identified, including the complex
brain gangliosides GD1a and GT1b (Yang et al., 1996), the Nogo
receptor family members NgR1 (Domeniconi et al., 2002; Liu
et al., 2002) and NgR2 (Venkatesh et al., 2005), paired Ig-like
receptor B (PirB) (Atwal et al., 2008), β1-integrin (Goh et al.,
2008), and low density lipoprotein receptor-related protein 1
(LRP1). Except for the interaction with LRP1, MAG binds to
its neuronal surface receptors in a sialic acid-dependent manner
(Robak et al., 2009; Stiles et al., 2013). Myelination and nodal
defects in B4galnt1 null mice, which lackmajor brain gangliosides
(including GD1a and GT1b), display striking similarities to Mag
null mice, suggesting that gangliosides may be the primary
receptors responsible for MAG-mediated axon protection
(Schnaar and Lopez, 2009). Whether NgR1, NgR2, PirB, β1-
integrin, or LRP1 play a role in MAG mediated axon protection
in vivo has not yet been addressed conclusively and will likely
require the generation of compound mutant mice to deal with
potential redundant functions among different MAG receptors.
MAG modulates the axonal cytoskeleton, affecting axon caliber,
neurofilament spacing (Yin et al., 1998), post-translational
modification of microtubules (Hsieh et al., 1994; Nguyen et al.,
2009), phosphorylation of MAP2 (Dashiell et al., 2002) and
activation of the RhoA/ROCK signaling pathway (Mimura et al.,
2006). In future studies it will be important to determine whether
the molecular mechanisms of MAG-mediated axon protection
and neurite outgrowth inhibition can be dissociated, and if
so, whether this can be exploited therapeutically to selectivity
promote axon protection while at the same time eliminating
neuronal growth inhibitory constraints imposed by MAG.
NogoA
NogoA is a membrane-associated protein that belongs to the
reticulon family (GrandPre et al., 2000). Originally identified
as a neurite growth inhibitory “activity” enriched in a spinal
cord white matter fraction (Caroni and Schwab, 1988; Caroni
et al., 1988), three laboratories described the molecular identity
of Nogo-A more than 15 years ago (Chen et al., 2000; GrandPre
et al., 2000; Prinjha et al., 2000). NogoA harbors at least two
distinct growth inhibitory motifs, Nogo-66 (Fournier et al.,
2001) and Nogo120 (Oertle et al., 2003). In the injured
spinal cord, acute antibody blockade of Nogo-A promotes axon
sprouting and is associated with improved behavioral outcomes
(Schnell and Schwab, 1990; Merkler et al., 2001; Liebscher
et al., 2005). NogoA is expressed by many cell types, though
its expression is highest in OLs and principal neurons in
brain regions with a heightened degree of network plasticity,
including the hippocampus and neocortex (Huber et al., 2002;
Zhang et al., 2014). In the OL lineage, NogoA appears to
be an important regulator of myelin development. Treating
oligodendrocyte precursor cells (OPCs) with a Nogo-A function-
blocking antibody impairs differentiation of OPCs into mature
OLs in vitro (Huang et al., 2012). Additionally, NogoA knockout
mice show reduced OPC differentiation in vivo (Chong et al.,
2012). Similar to Mag null mice, the optic nerves in NogoA
null mice are hypomeylinated during development, but not
in adulthood (Pernet et al., 2008). NogoA also participates
in contact-mediated competitive interactions between OLs to
regulate themyelogenic potential (Chong et al., 2012). Cocultures
of WT and NogoA null OPCs revealed that the spacing of myelin
internodes formed by WT OLs depends on NogoA expression
in neighboring OLs. This regulation is likely accomplished by
Nogo120, since bead-bound Nogo120 significantly inhibits the
number of myelin internodes formed per OL in culture. In
vivo, NogoA null mice show expansive and aberrant myelination,
including hypermyelination of the superficial layers in the
neocortex (Chong et al., 2012).
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OMgp
OMgp is a 110-kDa leucine-rich repeat protein linked to the
cell membrane by a glycosylphosphatidylinositol (GPI)-anchor.
OMgp is expressed by OLs and neurons in the CNS (Vourc’h
et al., 2003) and is also found in astrocytes (Zhang et al., 2014).
Two independent studies identified OMgp as a potent growth
inhibitory molecule enriched in CNS myelin (Kottis et al., 2002;
Wang et al., 2002). Compared to MAG and NogoA, significantly
less is known about the physiological role of OMgp. However,
there may be some degree of overlap, as OMgp, similar to NogoA
and MAG, associates with NgR1 and PirB. Analogous to NogoA,
antibody blockade of OMgp leads to impaired differentiation
of OPCs into mature OLs in vitro (Huang et al., 2012). OMgp
null mice display defects of the nodal and paranodal architecture
(Nie et al., 2006) and hypomyelination of the spinal cord that
correlates with slower propagation of ascending and descending
electrical impulses (Lee et al., 2011). OMgp was shown to be
enriched near nodes of Ranvier, where it reportedly blocks axon
collateral sprouting from non-myelinated segments (Huang et al.,
2005). However, a subsequent study, using the same anti-OMgp
antiserum inWT and OMgp knockout tissue, showed that OMgp
is not enriched at nodes (Chang et al., 2010). Additional studies
are needed to describe the physiological properties of OMgp
in vivo and to define the extent to which this underexplored
molecule contributes to aspects of axon-myelin communication.
CSPGs
Another prominent group of CNS regeneration inhibitors,
chondroitin sulfate proteoglycans (CSPGs), are extracellular
matrix (ECM) proteoglycans that consist of a protein core
with covalently attached glycosaminoglycan (GAG) side chains
(Properzi et al., 2003; Silver and Silver, 2014). CSPGs are secreted
by astrocytes, neurons, and oligodendrocytes (Ogawa et al.,
2001), and they are strongly enriched at the glial scar after
CNS injury where they inhibit regenerative growth and restrict
plasticity (Bradbury et al., 2002; Morgenstern et al., 2002; Silver
and Miller, 2004). CSPGs are a major component of the brain
ECM with developmentally regulated expression, therefore they
are thought to play a role in neural development, axon guidance,
and synaptic plasticity (Kwok et al., 2012). During development,
immature OLs express brevican precisely when they extend
processes to ensheathe axons (Ogawa et al., 2001), and loss
of brevican perturbs ECM distribution near nodes of Ranvier
in adulthood (Bekku et al., 2009). As discussed below, CSPGs
play important roles in visual system development and plasticity
(Pizzorusso et al., 2002), and also in the formation, refinement,
and modification of synaptic structures in other brain regions
(Orlando et al., 2012) and the protection of memories from
erasure (Gogolla et al., 2009).
CNS Regeneration Inhibitors Consolidate
Neuronal Architecture at the End of Critical
Periods
Proper formation, maintenance, and activity-dependent
modification of synaptic contacts may be achieved through
dynamic regulation of molecules that promote structural
plasticity and also molecules that stabilize existing structures
(Mironova andGiger, 2013; deWit andGhosh, 2014; Zagrebelsky
and Korte, 2014). Strong evidence that CNS regeneration
inhibitors may be involved in limiting neuronal plasticity stems
from work in the rodent visual system. In the juvenile brain,
normal development of the primary visual cortex involves a
CP of heightened plasticity. During the CP, visual experience
drives refinement of visual neuronal architecture, including the
formation of ocular dominance (OD) columns. Once the CP
is closed, mature networks are maintained and OD plasticity
is more restricted (Levelt and Hubener, 2012). Though most
extensively studied in the visual cortex, activity-dependent
refinement of neural circuits is not unique to the visual system.
CPs exist in many other brain regions and are important for the
acquisition of language and certain forms of higher cognitive
processing. Elegant studies by Pizzorusso et al. showed that
enzymatic digestion of CSPG glycosaminoglycan chains by local
infusion of chondroitinaseABC, a bacterial enzyme that digests
the GAG side chains on CSPGs, greatly augments OD plasticity
in the binocular zone of the adult visual cortex (Pizzorusso et al.,
2002). McGee and colleagues found that in NgR1 mutant mice,
there is no temporal limit to the CP, and robust OD plasticity
persists throughout adulthood (McGee et al., 2005). In a similar
vein, OD plasticity is extended in Nogo (McGee et al., 2005)
and PirB (Syken et al., 2006) mutant mice, indicating that CNS
regeneration inhibitors and their receptors function as negative
regulators of experience-driven neuronal plasticity at the end of
the CP in the visual system. Thus, one important physiological
function of CNS regeneration inhibitors is to consolidate
neuronal architecture established at the end of CPs, thereby
stabilizing microcircuits that are highly tuned and difficult to
assemble.
Neuronal Expression of Inhibitory Ligands and
their Receptors
CNS regeneration inhibitors are expressed by glia and neurons.
Nogo-A, OMgp and several CSPGs are expressed by neurons and
found along axons and dendrites (Mironova and Giger, 2013).
Interestingly, Nogo-A and OMgp are present in presynaptic
and post-synaptic density fractions isolated from the rodent
hippocampus (Lee et al., 2008; Raiker et al., 2010). In a similar
vein, NgR1 a receptor for Nogo-66, OMgp and CSPGs, is also
found in synaptic density fractions, as is PirB (Fournier et al.,
2001; Wang et al., 2002; Atwal et al., 2008; Filbin, 2008). PirB is a
member of the leukocyte immunoglobulin-like receptor family
(LILRB3), and compared to NgR1 it is much less prominently
expressed in the CNS (Raiker et al., 2010; Zhang et al., 2014).
The Nogo120 domain of NogoA does not interact with PirB or
members of the Nogo receptor family. A recent study identified
sphingosine 1 phosphate receptor 2 (S1PR2) as a novel receptor
for Nogo120 (Kempf et al., 2014). S1PR2 is expressed in
hippocampal neurons, and as discussed below, it is necessary for
Nogo120-elicited changes in synaptic function (Nie et al., 2006).
CSPGs are secreted by astrocytes and neurons, and they are
found at synaptic sites and enriched in perineuronal nets (PNNs)
(Orlando et al., 2012; Miao et al., 2014). A number of neuronal
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surface receptors bind CSPGs and inhibit neurite outgrowth
in vitro, including NgR1, NgR3, leukocyte common antigen-
related protein (LAR), and its homolog RPTPσ (Shen et al., 2009;
Fisher et al., 2011; Dickendesher et al., 2012). NgR1, LAR, and
RPTPσ are present both pre and post-synaptically (Mironova
and Giger, 2013; Takahashi and Craig, 2013). Challenges for
future studies, therefore, will be to dissect which CSPGs exert
their functions through which receptor complexes and to define
their functional relationship to different classes of ligands already
known to operate in a LAR family or Nogo receptor family
dependent manner.
CNS Regeneration Inhibitors Can Influence
Synaptic Structure and Density
Dendritic spines are specialized post-synaptic compartments
that receive excitatory inputs from presynaptic axon terminals.
Dendritic spines display various morphologies, ranging
from immature thin or filopodia-like protrusions to mature
mushroom-shaped structures. Spine morphology is thought
to reflect the maturity and strength of excitatory synaptic
connections (Sala and Segal, 2014). In the hippocampus
of NgR1 knockout mice, CA1 dendritic spines have a less
mature distribution profile than wild-type littermate controls,
suggesting that NgR1 is required for the proper development
or maintenance of mature spines (Lee et al., 2008). Studies with
Nogo receptor compound mutant mice revealed that loss of all
three NgR family members (NgR1, NgR2, and NgR3) increases
synaptic density in the juvenile hippocampus, suggesting that
NgRs function as negative regulators of synaptogenesis. In
primary hippocampal neurons, loss of any one NgR family
member increases dendritic spine density. In vivo, however, an
increase in spine density is only observed in NgR triple knockout
mice, suggesting some degree of functional redundancy among
these related molecules (Wills et al., 2012). In a recent study
NgR1 was reported to be a key molecule in limiting dendritic
spine turnover in the somatosensory cortex of adult mice
(Akbik et al., 2013). However, this finding was challenged by
a subsequent study that found no role for NgR1 in restricting
dendritic spine turnover using the same transgenic mouse
model (Park et al., 2014). It is unclear which NgR ligands are
responsible for regulation of synaptic density and dendritic spine
morphology, though CSPGs, NogoA, and OMgp are present in
synaptic density fractions and therefore are likely candidates
(Raiker et al., 2010; Takahashi and Craig, 2013). Similar to
NgR1, NogoA promotes spine maturation in hippocampal
pyramidal neurons. In hippocampal slice cultures, antibody
blockade of NogoA shifts dendritic spine morphology toward
a more immature phenotype but does not affect spine density
(Zagrebelsky et al., 2010). In vivo, administration of NogoA
function-blocking antibodies into the motor cortex of adult male
rats leads to a net increase in dendritic spine density due to an
increase in spine formation (Zemmar et al., 2014).
The correlation of ECM maturation with reduced spine
dynamics at the closure of the CP suggests that CSPGs,
since they are ECM components, may play an active role in
restricting spine formation and maturation. Indeed, treatment of
hippocampal slices with ChaseABC to digest perisynaptic CSPGs
increases dendritic spine density and formation of spinehead
protrusions through a mechanism that requires β1-integrin
(Orlando et al., 2012). In neuron-glia co-cultures, enzymatic
digestion of brevican and neurocan GAG chains promotes
formation of synaptic puncta (Pyka et al., 2011), suggesting
that CSPGs restrict synaptogenesis. CSPGs may restrict synapse
formation through a mechanism involving RPTPσ or NgRs since
mice lacking these receptors display increased dendritic spine
density and length in vivo (Horn et al., 2012; Wills et al., 2012).
Regulation of Synaptic Function
In the mature brain, alterations in neuronal structure are thought
to reflect prolonged changes in neuronal activity. Long-term
potentiation (LTP) and long-term depression (LTD) of synaptic
transmission are opposing forms of activity-dependent synaptic
strength modifications, and are thought to underlie aspects of
learning and memory formation (Siegelbaum and Kandel, 1991).
Neurotrophic factors such as fibroblast growth factors (FGFs)
promote neuronal growth and plasticity and may antagonize
the growth inhibitory effects of CNS regeneration inhibitors. In
acutely isolated hippocampal slices of WT mice, exogenously
applied FGF2 does not alter LTP at CA3-CA1 synapses. In
NgR1−/− slices, LTP at CA3-CA1 synapses is indistinguishable
from WT controls. However, exogenous application of FGF2
greatly increases LTP in NgR1−/− slices. Pharmacological studies
show that elevated LTP in NgR1−/− slices requires FGFR
kinase activity (Lee et al., 2008). In juvenile hippocampal
slices of NgR1−/− mice, NMDAR dependent LTD at CA3-
CA1 synapses was absent, suggesting that synaptic depression
requires NgR1 signaling (Lee et al., 2008). Moreover, treatment
of acute hippocampal slices with soluble Nogo66 or OMgp
suppresses hippocampal LTP in an NgR1-dependent manner
(Raiker et al., 2010). These results demonstrate that CNS
regeneration inhibitors and their receptors can regulate the
strength of synaptic transmission, and may accomplish this, in
part, by antagonizing growth promoting signaling pathways.
NogoA strongly attenuates LTP at hippocampal CA3-CA1
synapses, since it is observed that antibody blockade of the
Nogo120 region leads to increased LTP (Delekate et al.,
2011). Counter-intuitively, treatment of hippocampal slices with
soluble Nogo120 leads to an increase in LTP. This Nogo120-
mediated increase in LTP may be caused by rapid endocytosis of
NogoA (Joset et al., 2010), resulting in an opposite effect since
internalization of the receptor complex attenuates Nogo120
signaling. Surprisingly, recordings from acute hippocampal slices
of NogoA knockout mice show normal LTP and normal LTD
at CA3-CA1 synapses, suggesting that related mechanisms exist
that compensate for chronic loss of NogoA (Delekate et al.,
2011). Inhibition of the Nogo120 receptor S1PR2 enhances
LTP in the hippocampus and motor cortex of WT mice, but
not in NogoA knock-out mice (Kempf et al., 2014), indicating
that NogoA may restrict activity-dependent plasticity through
S1PR2. Collectively, these studies establish the Nogo120 region
of NogoA as a negative regulator of activity-dependent synaptic
plasticity.
CSPGs are known to influence activity-dependent synaptic
strength, but the mechanisms are less clear. Mice lacking
RPTPσ display altered basal synaptic transmission, including
greater paired-pulse facilitation along with increased frequency
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of miniature excitatory post-synaptic currents (mEPSCs) (Horn
et al., 2012). Additionally, RPTPσ null mice have reduced LTP, yet
enhanced novel object recognition memory (Horn et al., 2012).
These alterations in synaptic function may not be specific to
CSPGs, since RPTPσ, similar to NgR1 and NgR3, also interacts
with heparan sulfate proteoglycans (HSPGs) (Coles et al., 2011;
Dickendesher et al., 2012). The cross-talk between CSPG and
HSPG family members at the synapse, and in neural network
plasticity in general, is an exciting but underexplored issue.
Signaling Pathways
Collectively, the above studies suggest that an intricate cross-
talk occurs between growth promoting and growth inhibitory
signaling pathways to achieve proper regulation of synaptic
plasticity and stability. Cross-talk between CNS regeneration
inhibitors and growth factors that increase plasticity may occur
at multiple levels. This is well illustrated by examining how CNS
regeneration inhibitors antagonize brain-derived neurotrophic
factor (BDNF) signaling. At the cell surface, BDNF binds TrkB
to activate several growth promoting pathways, including mTOR
complex 1 (mTORC1) and MAP kinase/ERK. However, CSPG
binding to RPTPσ attenuates activity of TrkB (Kurihara and
Yamashita, 2012). At the level of cell signaling and protein
translation, BNDF-mediated activation of mTORC1 leads to
increased local protein synthesis at dendritic spines and promotes
synaptic plasticity (Tang et al., 2002; Leal et al., 2014). In
primary cortical neurons, pretreatment with crude CNS myelin
or recombinant Nogo66 attenuates the BDNF-mediated increase
in phosphorylation of p70S6K, a downstream target of mTORC1
(Raiker et al., 2010). This suggests that NogoA and NgR1
may restrict synaptic plasticity through negative regulation
of mTORC1 signaling, and perhaps the (local) translation of
synaptic proteins. In synaptic density fractions isolated from the
hippocampus of NgR1 mutant mice, levels of phosphorylated
ERK are significantly increased, suggesting that NgR1 negatively
regulates ERK signaling (Lee et al., 2008). Cross-talk might
also occur at the transcriptional level through regulation of
cAMP response element-binding protein (CREB). Elevating
cAMP levels overcomes myelin-mediated inhibition of neurite
outgrowth in a CREB dependent manner (Gao et al., 2004), while
Nogo120 decreases activation of CREB (Joset et al., 2010).
Role of CNS Inhibitory Molecules in CNS
Disorders
Many human neuropsychiatric disorders are associated with
defects in synaptic structure or function and may be caused by
a shift in excitatory/inhibitory balance (Pittenger, 2013). Given
that CNS myelin inhibitors play important roles in regulating
these processes, altered expression or function may contribute to
developmental brain disorders. In the aging brain, hippocampal
expression of several CNS regeneration inhibitors increases,
and correlates with, deficits in spatial learning and memory
(Vanguilder et al., 2012). NgR1 null mice show impaired memory
function, including impaired fear extinction and consolidation
(Park et al., 2014) as well as slow acquisition of a spatial memory
task (van Gaalen et al., 2012). Rats with reduced expression of
NogoA display defects in cognition and social behavior associated
with schizophrenia (Tews et al., 2013). Interestingly, mutations
in both human NgR1 and NogoA have been associated with
schizophrenia (Sinibaldi et al., 2004; Willi and Schwab, 2013).
Concluding Remarks
CNS regeneration inhibitors play important physiological roles
in the uninjured brain and spinal cord. The myelin-associated
inhibitors MAG, NogoA, and OMgp regulate myelin formation
and axon-myelin interactions. NogoA, OMgp, and CSPGs
regulate synapse formation and maturation, and they influence
activity-dependent synaptic strength. Growing evidence suggests
that some CNS regeneration inhibitors participate in an intricate
cross-talk with growth promotingmolecules at the level of several
key signaling molecules. This finely tuned balance of excitation
and inhibition in the developing and mature CNS may be
necessary for proper formation and function of neural networks.
The physiological role of these molecules raises important
considerations for therapeutic strategies designed to promote
neural regeneration following injury. The acquisition of a large
number of ligand-receptor systems that restrict neural network
plasticity may have been a prerequisite that enabled the evolution
of larger and more powerful neural networks. Larger and more
complex brains may be more vulnerable to aberrant changes in
synaptic connectivity and therefore, once fully developed, need
to be consolidated and protected by molecules that constrain
excessive network rearrangement. Following injury to the adult
CNS, molecules that restrict aberrant growth and plasticity
may be detrimental since they limit attempts to modify or
rebuild nearby networks to compensate for lost neural circuits.
Therefore, a deeper understanding of the physiological roles
played by CNS regeneration inhibitors is of great interest both
clinically and biologically.
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